IDEAYA Q4 profit slightly beats estimates

Reuters02-17
IDEAYA Q4 profit slightly beats estimates

Overview

  • Precision medicine oncology firm's Q4 EPS and net income slightly beat analyst expectations

  • Q4 collaboration revenue rose compared to the same period last year

  • Company anticipates topline results from Phase 2/3 trial in metastatic uveal melanoma by March end

Outlook

  • IDEAYA expects topline results from darovasertib trial by end of March 2026

  • Company anticipates three Phase 3 trials for darovasertib by H1 2026

  • IDEAYA plans IDE849 registrational study in SCLC by end of 2026

Result Drivers

  • CLINICAL TRIAL PROGRESS - IDEAYA completed full enrollment in its Phase 2/3 trial for metastatic uveal melanoma, with topline results expected by March end

  • PIPELINE EXPANSION - Co initiated IND filings for IDE034 and IDE574, expanding its clinical pipeline

  • FINANCIAL POSITION - IDEAYA reported $1.05 bln in cash and equivalents, expected to fund operations into 2030

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Collaboration Revenue

$10.88 mln

Q4 EPS

Beat

-$0.94

-$0.97 (17 Analysts)

Q4 Net Income

Slight Beat*

-$83.27 mln

-$83.37 mln (15 Analysts)

Q4 Profit From Operations

Beat

-$94.57 mln

-$96.32 mln (16 Analysts)

Q4 Operating Expenses

$105.45 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $48.00, about 58.6% above its February 13 closing price of $30.27

Press Release: ID:nPn6yX2DKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment